Search Results - "Fabbro, Michel"

Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer by Colombo, Pierre-Emmanuel, Fabbro, Michel, Theillet, Charles, Bibeau, Frédéric, Rouanet, Philippe, Ray-Coquard, Isabelle

“…Abstract Ovarian carcinoma is the most lethal gynaecologic malignancy. Despite wide initial sensibility to chemotherapy especially to platinum-based regimens,…”
Get full text

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group by Freyer, Gilles, Floquet, Anne, Tredan, Olivier, Carrot, Aurore, Langlois-Jacques, Carole, Lopez, Jonathan, Selle, Frédéric, Abdeddaim, Cyril, Leary, Alexandra, Dubot-Poitelon, Coraline, Fabbro, Michel, Gladieff, Laurence, Lamuraglia, Michele

“…Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely…”
Get full text

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial by Monk, Bradley J, Prof, Poveda, Andrés, MD, Vergote, Ignace, MD, Raspagliesi, Francesco, MD, Fujiwara, Keiichi, MD, Bae, Duk-Soo, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, MD, Provencher, Diane M, MD, Karlan, Beth Y, MD, Lhommé, Catherine, MD, Richardson, Gary, MD, Rincón, Dolores Gallardo, MD, Coleman, Robert L, MD, Herzog, Thomas J, MD, Marth, Christian, PhD, Brize, Arija, MD, Fabbro, Michel, MD, Redondo, Andrés, MD, Bamias, Aristotelis, PhD, Tassoudji, Marjan, MS, Navale, Lynn, MS, Warner, Douglas J, MD, Oza, Amit M, MD

“…Summary Background Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to…”
Get full text

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network by Langner-Lemercier, Sophie, Houillier, Caroline, Soussain, Carole, Ghesquières, Hervé, Chinot, Olivier, Taillandier, Luc, Soubeyran, Pierre, Lamy, Thierry, Morschhauser, Franck, Benouaich-Amiel, Alexandra, Ahle, Guido, Moles-Moreau, Marie-Pierre, Moluçon-Chabrot, Cécile, Bourquard, Pascal, Damaj, Ghandi, Jardin, Fabrice, Larrieu, Delphine, Gyan, Emmanuel, Gressin, Remy, Jaccard, Arnaud, Choquet, Sylvain, Brion, Annie, Casasnovas, Olivier, Colin, Philippe, Reman, Oumedaly, Tempescul, Adrian, Marolleau, Jean-Pierre, Fabbro, Michel, Naudet, Florian, Hoang-Xuan, Khê, Houot, Roch

“…Treatment of relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) is poorly defined, because randomized trials and large studies are lacking. The aim of this…”
Get full text

Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group by Freyer, Gilles, Floquet, Anne, Tredan, Olivier, Carrot, Aurore, Langlois-Jacques, Carole, Lopez, Jonathan, Selle, Frédéric, Abdeddaim, Cyril, Leary, Alexandra, Dubot-Poitelon, Coraline, Fabbro, Michel, Gladieff, Laurence, Lamuraglia, Michele

Get full text

HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial by Fabbro, Michel, Lamy, Pierre-Jean, Touraine, Célia, Floquet, Anne, Ray-Coquard, Isabelle, Mollevi, Caroline

“…HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients…”
Get full text

Bevacizumab in recurrent WHO grades II-III glioma by Annakib, Soufyan, Rigau, Valérie, Darlix, Amélie, Gozé, Catherine, Duffau, Hugues, Bauchet, Luc, Jarlier, Marta, Fabbro, Michel

“…The management of recurrent WHO grades II-III (rGII-III) glioma is not well established. This study describes the clinical outcomes in patients who received…”
Get full text

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer by Vendrell, Julie A., Ban, Iulian O., Solassol, Isabelle, Audran, Patricia, Cabello-Aguilar, Simon, Topart, Delphine, Lindet-Bourgeois, Clothilde, Colombo, Pierre-Emmanuel, Legouffe, Eric, D’Hondt, Véronique, Fabbro, Michel, Solassol, Jérôme

“…Purpose: The introduction of PARP inhibitors (PARPis) as a treatment option for patients with high-grade serous ovarian cancer (HGSOC) modified the approach of…”
Get full text

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research by Moniot, Aurélie, Schneider, Christophe, Chardin, Laure, Yaniz-Galende, Elisa, Genestie, Catherine, Etiennot, Marion, Henry, Aubéri, Drelon, Coralie, Le Formal, Audrey, Langlois, Benoit, Venat, Laurence, Louvet, Christophe, Favier, Laure, Lortholary, Alain, Berton-Rigaud, Dominique, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Dubot, Coraline, Kurtz, Jean Emmanuel, Bonichon Lamichhane, Nathalie, Pujade-Lauraine, Éric, Jeanne, Albin, Leary, Alexandra, Dedieu, Stéphane

“…Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the…”
Get full text

PD1 and PDL1 expression in primary central nervous system diffuse large B‐cell lymphoma are frequent and expression of PD1 predicts poor survival by Four, Marion, Cacheux, Valère, Tempier, Ariane, Platero, Dolorès, Fabbro, Michel, Marin, Grégory, Leventoux, Nicolas, Rigau, Valérie, Costes‐Martineau, Valérie, Szablewski, Vanessa

“…Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) is a rare and aggressive type of diffuse large B‐cell lymphoma (DLBCL) whit poorly…”
Get full text

Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer by Alix-Panabières, Catherine, Vendrell, Jean-Pierre, Slijper, Monique, Pellé, Olivier, Barbotte, Eric, Mercier, Grégoire, Jacot, William, Fabbro, Michel, Pantel, Klaus

“…We evaluated whether CK19, one of the main cytoskeleton proteins of epithelial cells, is released as full-length protein from viable tumor cells and whether…”
Get full text

Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life by Blonski, Marie, Taillandier, Luc, Herbet, Guillaume, Maldonado, Igor Lima, Beauchesne, Patrick, Fabbro, Michel, Campello, Chantal, Gozé, Catherine, Rigau, Valérie, Moritz-Gasser, Sylvie, Kerr, Christine, Rudà, Roberta, Soffietti, Riccardo, Bauchet, Luc, Duffau, Hugues

“…Diffuse WHO grade II (GIIG) may be unresectable when involving critical structures. To assess the feasibility and functional tolerance (cognition and quality…”
Get full text

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients by de la Rochefordiere, Anne, Kamal, Maud, Floquet, Anne, Thomas, Laurence, Petrow, Peter, Petit, Thierry, Pop, Marius, Fabbro, Michel, Kerr, Christine, Joly, Florence, Sevin, Emmanuel, Maillard, Sophie, Curé, Hervé, Weber, Béatrice, Brunaud, Claire, Minsat, Mathieu, Gonzague, Laurence, Berton-Rigaud, Dominique, Aumont, Maud, Gladieff, Laurence, Peignaux, Karine, Bernard, Virginie, Leroy, Quentin, Bieche, Ivan, Margogne, Audrey, Nadan, AnaTereza, Fourchotte, Virginie, Diallo, Alhassane, Asselain, Benard, Plancher, Corine, Armanet, Sébastien, Beuzeboc, Philippe, Scholl, Suzy M

“…EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used…”
Get full text

Detection and characterization of putative metastatic precursor cells in cancer patients by Alix-Panabières, Catherine, Vendrell, Jean-Pierre, Pellé, Olivier, Rebillard, Xavier, Riethdorf, Sabine, Müller, Volkmar, Fabbro, Michel, Pantel, Klaus

“…SCs for the circulating rumor antigens mucin 1 (MUC1) or prostate-specific antigen (PSA) were detected in the majority of patiente with metastatic breast…”
Get full text

French Brain Tumor DataBase: 5-Year Histological Results on 25 756 Cases by Rigau, Valérie, Zouaoui, Sonia, Mathieu-Daudé, Hélène, Darlix, Amélie, Maran, Aurélie, Trétarre, Brigitte, Bessaoud, Faiza, Bauchet, Fabienne, Attaoua, Redha, Fabbro-Peray, Pascale, Fabbro, Michel, Kerr, Christine, Taillandier, Luc, Duffau, Hugues, Figarella-Branger, Dominique, Costes, Valérie, Bauchet, Luc

“…This work aimed to prospectively record all primary central nervous system tumor (PCNST) cases in France, for which histological diagnosis is available. The…”
Get full text

Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group by Mourksi, Nour‐El‐Houda, Dalban, Cécile, Colombe‐Vermorel, Amélie, Odeyer, Laetitia, Simioni, Valentin, Frenel, Jean‐Sébastien, Fabbro, Michel, Bazan, Fernando, Abadie‐Lacourtoisie, Sophie, Coquan, Elodie, Martinez, Séverine, Garin, Gwenaelle, Tabone‐Eglinger, Séverine, Treilleux, Isabelle, Chabaud, Sylvie, Pérol, David, Ray‐Coquard, Isabelle, Heudel, Pierre‐Etienne, Diaz, Jean‐Jacques, Marcel, Virginie

“…Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the…”
Get full text

Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients by Blonski, Marie, Pallud, Johan, Gozé, Catherine, Mandonnet, Emmanuel, Rigau, Valérie, Bauchet, Luc, Fabbro, Michel, Beauchesne, Patrick, Baron, Marie-Hélène, Fontaine, Denys, Peruzzi, Philippe, Darlix, Amélie, Duffau, Hugues, Taillandier, Luc

“…The involvement of eloquent brain areas may preclude the total/subtotal surgical resection of diffuse low-grade gliomas (DLGGs). The feasibility and functional…”
Get full text

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study by Fabbro, Michel, Jacot, William, Jarlier, Marta, Guiu, Séverine, D'Hondt, Véronique, Pouderoux, Stéphane, Champoiral, Patrice, Janiszewski, Chloé, Nicklès, Isabelle

“…Background Acceptability and tolerance of chemotherapy on patients treated for breast cancer remain challenging. Complementary approaches such as hypnosis may…”
Get full text

Metastatic Paraplegia and Vital Prognosis: Perspectives and Limitations for Rehabilitation Care. Part 1 by Fattal, Charles, MD, PhD, Fabbro, Michel, MD, Gelis, Anthony, MD, Bauchet, Luc, MD, PhD

“…Abstract Fattal C, Fabbro M, Gelis A, Bauchet L. Metastatic paraplegia and vital prognosis: perspectives and limitations for rehabilitation care. Part 1…”
Get full text

Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy by Neron, Mathias, Guille, Arnaud, Allegre, Lucie, Colombo, Pierre-Emmanuel, Leaha, Cristina, Adelaide, José, Carbuccia, Nadine, Courtier, Frédéric, Boissiere, Florence, Crapez, Evelyne, Fabbro, Michel, Gouy, Sébastien, Mamessier, Emilie, Lambaudie, Éric, Birnbaum, Daniel, Bertucci, François, Chaffanet, Max

“…Hormone therapy (HT) is an effective treatment for metastatic endometrial carcinoma (mEC), with limited toxicity and low cost. We focused on molecular analysis…”
Get full text